Table 2.
Comparison of adverse events observed with linezolid and vancomycin in intent-to-treat population
| Adverse event | Linezolid No (%) (n = 597) |
Vancomycin No (%) (n = 587) |
|---|---|---|
| Anemia | 30 (5.2) | 42 (7.2) |
| Cardiac arrest | 11 (1.8) | 13 (2.2) |
| Pancreatitis | 5 (0.8) | 1 (0.2) |
| Pancytopenia/neutropenia | 4 (0.6) | 2 (0.4) |
| Paresthesia | 0 | 1 (0.2) |
| Polyneuropathy | 0 | 1 (0.2) |
| Renal failure | 22 (3.7) | 43 (7.3) |
| Thrombocytopenia | 8 (1.3) | 13 (2.2) |
Note: Reprinted from Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study: Clin Infect Dis. 2012;54(5):621–629 by permission of Oxford University Press.42